Guanfacine vs Methylphenidate Side Effects
Guanfacine and methylphenidate have distinctly different side effect profiles: guanfacine primarily causes sedation-related effects (somnolence, fatigue, dizziness) and cardiovascular depression (bradycardia, hypotension), while methylphenidate causes stimulant-related effects including decreased appetite, insomnia, and cardiovascular stimulation (increased heart rate and blood pressure).
Guanfacine Side Effects
Most Common Effects:
- Somnolence/sedation (10-39% depending on dose) - most frequent reason for discontinuation 1, 2
- Dry mouth (10-54% in dose-dependent manner) 3
- Fatigue and weakness (asthenia) (6-12%) 2
- Dizziness (6-15%) 3
- Irritability, headache, abdominal pain 1
- Constipation (5-16%) 3
Cardiovascular Effects:
- Decreased heart rate (bradycardia) 1, 2
- Decreased blood pressure (hypotension) 1, 2
- Important: Paradoxical hypertension may occur early after ingestion 4
- Critical warning: Rebound hypertension can occur with abrupt discontinuation - must taper off gradually 1
Less Common but Notable:
Methylphenidate Side Effects
While the provided evidence focuses primarily on guanfacine, the guidelines note that methylphenidate as a stimulant has a contrasting profile:
Cardiovascular Effects:
- Increased heart rate and blood pressure (opposite of guanfacine) 1
- Extremely low risk of serious cardiovascular events 1
Common Stimulant Effects:
- Decreased appetite 1
- Growth delays in first 1-2 years (returns to expected trajectory after 2-3 years) 1
- Initial insomnia
- Gastrointestinal symptoms
Key Clinical Distinctions
Guanfacine causes CNS depression; methylphenidate causes CNS stimulation. This fundamental difference means:
- Sedation vs Activation: Guanfacine causes somnolence (10-39%), while methylphenidate typically causes alertness/insomnia
- Cardiovascular Direction: Guanfacine lowers HR/BP; methylphenidate raises HR/BP
- Appetite: Guanfacine has minimal appetite effects; methylphenidate commonly decreases appetite
- Onset of Adverse Effects: Guanfacine side effects are most prominent early and tend to decrease over time 3
Tolerability Profile
Guanfacine:
- Dropout rates: 2-32% depending on dose (higher doses = more dropouts) 3
- Most common dropout reasons: dry mouth, somnolence, dizziness, fatigue, weakness, constipation 3
- Most adverse effects are mild to moderate and tend to diminish with continued dosing 3
Combined Treatment: When guanfacine and methylphenidate are used together, the side effect profile resembles guanfacine monotherapy, with sedation, somnolence, lethargy, and fatigue being greater in guanfacine-containing regimens 5. However, combination therapy is generally well-tolerated with no unique adverse events compared to monotherapies 6.
Critical Safety Considerations
For Guanfacine:
- Obtain cardiac history before starting 1
- Monitor for hypotension/bradycardia 2
- Never discontinue abruptly - must taper to avoid rebound hypertension 1
- Dose-dependent side effects: higher doses (2-3 mg) have substantially more adverse effects than lower doses (0.5-1 mg) 3
For Methylphenidate:
- Obtain cardiac history and consider ECG if risk factors present 1
- Monitor growth parameters in children 1
- Assess for cardiovascular stimulation
The evidence consistently shows guanfacine has less sedative effects than clonidine due to higher specificity for α2A receptors 2, making it preferable among alpha-2 agonists when sedation is a concern.